Xue, Zheng <br/><br/>
MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.  [electronic resource] 

 -  Cell research  07 2018 
 - 719-729 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1748-7838 
<br/><br/><label>Standard No.: </label>10.1038/s41422-018-0044-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Benzimidazoles--pharmacology<br/>Breast Neoplasms--drug therapy<br/>Cell Line, Tumor<br/>Colonic Neoplasms--drug therapy<br/>Drug Resistance, Neoplasm--genetics<br/>Female<br/>Heterografts<br/>Humans<br/>Loss of Function Mutation<br/>MAP Kinase Kinase 4--antagonists & inhibitors<br/>MAP Kinase Kinase Kinase 1--antagonists & inhibitors<br/>MAP Kinase Signaling System--drug effects<br/>Male<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors<br/>Prostatic Neoplasms--drug therapy<br/>Protein Kinase Inhibitors--pharmacology